Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
2.7M
Short interest
settlement 2026-10-15
12.8
Days to cover
+1.7 days vs prior
57.1%
Short share of volume
2026-11-02
287
Fails to deliver
settlement 2026-09-21
Tue 3 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in RIGL is 2,732,739 shares, down 459,072 shares over the last month. Over the last 48 readings it ranged from 456,924 shares (15 January 2025) to 4,121,844 shares (15 April 2026). At the reported average volume of 213K shares a day that is 12.8 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/rigl" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 2,732,739 | -4.3% | 213,492 | 12.80 |
| 2026-09-30 | 2,855,433 | -10.5% | 256,338 | 11.14 |
| 2026-09-15 | 3,191,811 | +0.3% | 201,576 | 15.83 |
| 2026-08-31 | 3,182,110 | -0.7% | 349,183 | 9.11 |
| 2026-08-14 | 3,203,364 | +3.6% | 328,254 | 9.76 |
| 2026-07-31 | 3,092,899 | -2.0% | 293,137 | 10.55 |
| 2026-07-15 | 3,157,453 | -2.9% | 401,367 | 7.87 |
| 2026-06-30 | 3,252,727 | -6.0% | 452,745 | 7.18 |
| 2026-06-15 | 3,458,879 | -12.1% | 309,283 | 11.18 |
| 2026-05-29 | 3,934,552 | -0.3% | 327,363 | 12.02 |
| 2026-05-15 | 3,945,787 | +0.3% | 526,989 | 7.49 |
| 2026-04-30 | 3,935,324 | -4.5% | 325,493 | 12.09 |
| 2026-04-15 | 4,121,844 | +8.2% | 365,938 | 11.26 |
| 2026-03-31 | 3,810,645 | +2.2% | 287,295 | 13.26 |
| 2026-03-13 | 3,729,897 | -0.6% | 528,099 | 7.06 |
| 2026-02-27 | 3,752,643 | -1.1% | 288,751 | 13.00 |
| 2026-02-13 | 3,793,344 | +1.7% | 266,185 | 14.25 |
| 2026-01-30 | 3,730,076 | +0.8% | 307,647 | 12.12 |
| 2026-01-15 | 3,701,312 | +7.6% | 550,620 | 6.72 |
| 2025-12-31 | 3,439,339 | +21.8% | 588,760 | 5.84 |
| 2025-12-15 | 2,824,418 | +2.4% | 543,071 | 5.20 |
| 2025-11-28 | 2,757,766 | -11.4% | 663,797 | 4.15 |
| 2025-11-14 | 3,111,107 | -9.4% | 897,347 | 3.47 |
| 2025-10-31 | 3,435,660 | -1.3% | 390,039 | 8.81 |
| 2025-10-15 | 3,480,017 | +24.9% | 538,612 | 6.46 |
| 2025-09-30 | 2,787,310 | +26.7% | 755,206 | 3.69 |
| 2025-09-15 | 2,200,707 | +9.7% | 644,767 | 3.41 |
| 2025-08-29 | 2,005,855 | +1.0% | 875,165 | 2.29 |
| 2025-08-15 | 1,985,792 | -20.9% | 1,013,387 | 1.96 |
| 2025-07-31 | 2,511,219 | +5.0% | 175,412 | 14.32 |
| 2025-07-15 | 2,392,423 | +10.1% | 193,479 | 12.37 |
| 2025-06-30 | 2,172,820 | +3.6% | 231,194 | 9.40 |
| 2025-06-13 | 2,097,034 | +5.5% | 173,396 | 12.09 |
| 2025-05-30 | 1,988,105 | -4.5% | 215,369 | 9.23 |
| 2025-05-15 | 2,081,837 | +12.4% | 255,640 | 8.14 |
| 2025-04-30 | 1,851,654 | -0.6% | 149,760 | 12.36 |
| 2025-04-15 | 1,862,313 | +3.1% | 227,909 | 8.17 |
| 2025-03-31 | 1,805,607 | +15.1% | 253,557 | 7.12 |
| 2025-03-14 | 1,568,375 | +6.1% | 262,083 | 5.98 |
| 2025-02-28 | 1,478,509 | +9.7% | 182,623 | 8.10 |
| 2025-02-14 | 1,348,285 | +140.4% | 313,043 | 4.31 |
| 2025-01-31 | 560,734 | +22.7% | 208,149 | 2.69 |
| 2025-01-15 | 456,924 | -43.4% | 229,498 | 1.99 |
| 2024-12-31 | 807,502 | +27.1% | 392,130 | 2.06 |
| 2024-12-13 | 635,441 | +34.9% | 225,568 | 2.82 |
| 2024-11-29 | 470,932 | +1.8% | 172,116 | 2.74 |
| 2024-11-15 | 462,667 | -30.0% | 409,173 | 1.13 |
| 2024-10-31 | 661,194 | -7.9% | 96,542 | 6.85 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of RIGL volume is 57.1%, down 3.1 points over the last five sessions. Over the last 30 readings it ranged from 46.0% (30 October 2026) to 84.4% (6 October 2026). The latest reading is 4.9 points below the 30-session average of 61.9%, on 60K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 34K | 60K | 57.1% | 0 |
| 2026-10-30 | 24K | 52K | 46.0% | 25 |
| 2026-10-29 | 29K | 53K | 53.8% | 0 |
| 2026-10-28 | 41K | 78K | 52.6% | 0 |
| 2026-10-27 | 23K | 41K | 55.1% | 0 |
| 2026-10-26 | 37K | 62K | 60.1% | 0 |
| 2026-10-23 | 19K | 40K | 47.6% | 2 |
| 2026-10-22 | 23K | 42K | 55.0% | 0 |
| 2026-10-21 | 30K | 54K | 55.3% | 210 |
| 2026-10-20 | 34K | 55K | 61.0% | 0 |
| 2026-10-19 | 39K | 57K | 68.7% | 1 |
| 2026-10-16 | 32K | 48K | 65.9% | 0 |
| 2026-10-15 | 31K | 51K | 61.3% | 100 |
| 2026-10-14 | 31K | 51K | 61.4% | 0 |
| 2026-10-13 | 31K | 45K | 69.4% | 0 |
| 2026-10-12 | 38K | 57K | 66.4% | 20 |
| 2026-10-09 | 51K | 111K | 46.3% | 0 |
| 2026-10-08 | 53K | 75K | 71.2% | 100 |
| 2026-10-07 | 70K | 96K | 73.1% | 0 |
| 2026-10-06 | 61K | 73K | 84.4% | 0 |
| 2026-10-05 | 69K | 104K | 66.5% | 3 |
| 2026-10-02 | 43K | 56K | 76.4% | 0 |
| 2026-10-01 | 44K | 70K | 62.2% | 37 |
| 2026-09-30 | 39K | 69K | 56.2% | 0 |
| 2026-09-29 | 30K | 50K | 59.9% | 0 |
| 2026-09-28 | 28K | 41K | 67.8% | 5 |
| 2026-09-25 | 27K | 46K | 59.5% | 9 |
| 2026-09-24 | 36K | 50K | 73.4% | 2 |
| 2026-09-23 | 35K | 54K | 64.2% | 0 |
| 2026-09-22 | 37K | 62K | 59.6% | 100 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 21 September 2026, the fails-to-deliver balance in RIGL is 287 shares, up 168 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (10 July 2026) to 12,546 shares (8 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-21 | 287 | $46.64 | $13K |
| 2026-09-10 | 119 | $47.22 | $6K |
| 2026-09-09 | 5 | $47.37 | $237 |
| 2026-09-03 | 5 | $49.42 | $247 |
| 2026-09-01 | 50 | $46.18 | $2K |
| 2026-08-24 | 500 | $45.89 | $23K |
| 2026-08-13 | 9 | $41.87 | $377 |
| 2026-08-04 | 2,018 | $37.43 | $76K |
| 2026-07-29 | 216 | $38.50 | $8K |
| 2026-07-16 | 131 | $41.18 | $5K |
| 2026-07-14 | 8,429 | $41.30 | $348K |
| 2026-07-13 | 169 | $42.55 | $7K |
| 2026-07-10 | 1 | $43.76 | $44 |
| 2026-07-08 | 12,546 | $42.56 | $534K |
| 2026-07-07 | 2,176 | $40.26 | $88K |
| 2026-07-06 | 4,355 | $38.72 | $169K |
| 2026-07-02 | 3 | $38.29 | $115 |
| 2026-07-01 | 71 | $39.12 | $3K |
| 2026-06-29 | 2,778 | $38.69 | $107K |
| 2026-06-25 | 356 | $36.55 | $13K |
| 2026-06-23 | 753 | $35.73 | $27K |
| 2026-06-16 | 529 | $33.42 | $18K |
| 2026-06-15 | 575 | $32.85 | $19K |
| 2026-06-12 | 3,907 | $32.08 | $125K |
| 2026-06-11 | 2,311 | $30.91 | $71K |
| 2026-06-10 | 3,564 | $30.72 | $109K |
| 2026-06-08 | 6,384 | $29.93 | $191K |
| 2026-05-27 | 3 | $29.17 | $88 |
| 2026-05-26 | 37 | $29.01 | $1K |
| 2026-05-19 | 3,929 | $28.61 | $112K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for RIGL in the last 90 days. The most recent filings are listed below. Latest filing: Schorno Dean L (EVP & Chief Financial Officer) on 2026-09-02.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Schorno Dean L | EVP & Chief Financial Officer | Exercise or conversion | 1K | $24.20 | $31K | 83K |
| 2026-09-02 | Schorno Dean L | EVP & Chief Financial Officer | Exercise or conversion | 2K | $24.20 | $48K | 82K |
| 2026-09-02 | Schorno Dean L | EVP & Chief Financial Officer | Exercise or conversion | 620 | $18.70 | $12K | 80K |
| 2026-09-02 | Schorno Dean L | EVP & Chief Financial Officer | Exercise or conversion | 694 | $12.70 | $9K | 79K |
| 2026-09-01 | Schorno Dean L | EVP & Chief Financial Officer | Tax withholding | 928 | $47.50 | $44K | 78K |
| 2026-09-01 | Santos David A | EVP, Chief Commercial Officer | Tax withholding | 874 | $47.50 | $42K | 62K |
| 2026-09-01 | RODRIGUEZ RAUL R | CEO, President | Tax withholding | 2K | $47.50 | $115K | 273K |
| 2026-09-01 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | Tax withholding | 877 | $47.50 | $42K | 51K |
| 2026-07-08 | HANNAH ALISON L. | EVP, Chief Medical Officer | Grant | 24K | $0.00 | $0 | 35K |
| 2026-06-22 | Ali-Jackson Kamil | Director | Sell | 3K | $35.00 | $88K | 10K |
| 2026-06-01 | Schorno Dean L | EVP & Chief Financial Officer | Tax withholding | 928 | $29.86 | $28K | 79K |
| 2026-06-01 | Schorno Dean L | EVP & Chief Financial Officer | Exercise or conversion | 2K | $12.70 | $28K | 80K |
| 2026-06-01 | Schorno Dean L | EVP & Chief Financial Officer | Exercise or conversion | 1K | $18.70 | $22K | 78K |
| 2026-06-01 | Santos David A | EVP, Chief Commercial Officer | Tax withholding | 874 | $29.86 | $26K | 62K |
| 2026-06-01 | Rojkjaer Lisa | EVP, Chief Medical Officer | Tax withholding | 850 | $29.86 | $25K | 34K |
| 2026-06-01 | RODRIGUEZ RAUL R | CEO, President | Tax withholding | 2K | $29.86 | $72K | 280K |
| 2026-06-01 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | Tax withholding | 877 | $29.86 | $26K | 51K |
| 2026-05-26 | Ali-Jackson Kamil | Director | Sell | 3K | $29.17 | $73K | 13K |
| 2026-05-15 | Wasman Jane | Director | Grant | 6K | $0.00 | $0 | 18K |
| 2026-05-15 | MOOS WALTER H | Director | Grant | 6K | $0.00 | $0 | 18K |
| 2026-05-15 | MILLER MICHAEL PATRICK | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2026-05-15 | LAPOINTE ANTHONY GREGG | Director | Grant | 6K | $0.00 | $0 | 18K |
| 2026-05-15 | HANNAH ALISON L. | Director | Grant | 6K | $0.00 | $0 | 16K |
| 2026-05-15 | Frohlich Mark W | Director | Grant | 6K | $0.00 | $0 | 7K |
| 2026-05-15 | Ali-Jackson Kamil | Director | Grant | 6K | $0.00 | $0 | 15K |
| 2026-02-20 | MOOS WALTER H | Director | Sell | 4K | $36.36 | $145K | 13K |
| 2026-02-20 | MOOS WALTER H | Director | Exercise or conversion | 4K | $24.00 | $96K | 17K |
| 2026-02-17 | RODRIGUEZ RAUL R | CEO, President | Grant | 54K | $0.00 | $0 | 282K |
| 2026-02-17 | Santos David A | EVP, Chief Commercial Officer | Grant | 19K | $0.00 | $0 | 63K |
| 2026-02-17 | Rojkjaer Lisa | EVP, Chief Medical Officer | Grant | 19K | $0.00 | $0 | 35K |
| 2026-02-17 | Schorno Dean L | EVP & Chief Financial Officer | Grant | 21K | $0.00 | $0 | 76K |
| 2026-02-17 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | Grant | 19K | $0.00 | $0 | 52K |
| 2026-02-10 | Santos David A | EVP, Chief Commercial Officer | Tax withholding | 4K | $34.62 | $123K | 43K |
| 2026-02-10 | Schorno Dean L | EVP & Chief Financial Officer | Tax withholding | 4K | $34.62 | $123K | 56K |
| 2026-02-10 | Rojkjaer Lisa | EVP, Chief Medical Officer | Tax withholding | 4K | $34.62 | $130K | 16K |
| 2026-02-10 | RODRIGUEZ RAUL R | CEO, President | Tax withholding | 8K | $34.62 | $263K | 228K |
| 2026-02-10 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | Tax withholding | 4K | $34.62 | $123K | 32K |
| 2026-02-02 | Santos David A | EVP, Chief Commercial Officer | Tax withholding | 6K | $36.01 | $206K | 47K |
| 2026-02-02 | Schorno Dean L | EVP & Chief Financial Officer | Tax withholding | 5K | $36.01 | $198K | 59K |
| 2026-02-02 | RODRIGUEZ RAUL R | CEO, President | Tax withholding | 14K | $36.01 | $508K | 236K |
| 2026-02-02 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | Tax withholding | 4K | $36.01 | $143K | 36K |
| 2026-01-26 | RODRIGUEZ RAUL R | CEO, President | Exercise or conversion | 40K | $27.40 | $1.1M | 285K |
| 2026-01-26 | RODRIGUEZ RAUL R | CEO, President | Tax withholding | 35K | $37.00 | $1.3M | 250K |
| 2026-01-26 | RODRIGUEZ RAUL R | CEO, President | Tax withholding | 35K | $37.00 | $1.3M | 245K |
| 2026-01-26 | RODRIGUEZ RAUL R | CEO, President | Exercise or conversion | 40K | $27.40 | $1.1M | 280K |
| 2025-12-22 | Schorno Dean L | EVP & Chief Financial Officer | Exercise or conversion | 2K | $18.70 | $31K | 64K |
| 2025-12-22 | Schorno Dean L | EVP & Chief Financial Officer | Exercise or conversion | 3K | $24.20 | $69K | 63K |
| 2025-12-22 | Schorno Dean L | EVP & Chief Financial Officer | Exercise or conversion | 2K | $20.00 | $40K | 60K |
| 2025-05-23 | Frohlich Mark W | Director | Grant | 1K | $0.00 | $0 | 1K |
| 2025-05-23 | HANNAH ALISON L. | Director | Grant | 3K | $0.00 | $0 | 11K |
| 2025-05-23 | LAPOINTE ANTHONY GREGG | Director | Grant | 3K | $0.00 | $0 | 13K |
| 2025-05-23 | MOOS WALTER H | Director | Grant | 3K | $0.00 | $0 | 13K |
| 2025-05-23 | Ali-Jackson Kamil | Director | Grant | 3K | $0.00 | $0 | 9K |
| 2025-05-23 | Wasman Jane | Director | Grant | 3K | $0.00 | $0 | 13K |
| 2025-02-05 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | Sell | 1K | $21.93 | $29K | 39K |
| 2025-02-05 | RODRIGUEZ RAUL R | CEO, President | Sell | 4K | $21.93 | $96K | 239K |
| 2025-02-05 | Santos David A | EVP, Chief Commercial Officer | Sell | 2K | $21.93 | $39K | 52K |
| 2025-02-05 | Schorno Dean L | EVP & Chief Financial Officer | Sell | 2K | $21.93 | $38K | 57K |
| 2025-02-04 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | Sell | 1K | $20.92 | $30K | 40K |
| 2025-02-04 | RODRIGUEZ RAUL R | CEO, President | Sell | 5K | $20.92 | $104K | 244K |
| 2025-02-04 | Santos David A | EVP, Chief Commercial Officer | Sell | 2K | $20.92 | $44K | 54K |
| 2025-02-04 | Schorno Dean L | EVP & Chief Financial Officer | Sell | 2K | $20.92 | $43K | 59K |
| 2025-01-29 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | Grant | 20K | $0.00 | $0 | 42K |
| 2025-01-29 | Santos David A | EVP, Chief Commercial Officer | Grant | 20K | $0.00 | $0 | 56K |
| 2025-01-29 | Schorno Dean L | EVP & Chief Financial Officer | Grant | 20K | $0.00 | $0 | 61K |
| 2025-01-29 | RODRIGUEZ RAUL R | CEO, President | Grant | 42K | $0.00 | $0 | 249K |
| 2025-01-29 | Rojkjaer Lisa | EVP, Chief Medical Officer | Grant | 20K | $0.00 | $0 | 20K |
| 2025-01-24 | RODRIGUEZ RAUL R | CEO, President | Tax withholding | 44K | $22.17 | $977K | 207K |
| 2025-01-24 | RODRIGUEZ RAUL R | CEO, President | Exercise or conversion | 45K | $21.40 | $963K | 250K |
| 2025-01-24 | RODRIGUEZ RAUL R | CEO, President | Exercise or conversion | 45K | $21.40 | $963K | 251K |
| 2025-01-24 | RODRIGUEZ RAUL R | CEO, President | Tax withholding | 44K | $22.17 | $977K | 206K |
| 2024-05-25 | Ali-Jackson Kamil | Director | Grant | 25K | $0.00 | $0 | 69K |
| 2024-05-25 | HANNAH ALISON L. | Director | Grant | 25K | $0.00 | $0 | 81K |
| 2024-05-25 | Kotzin Brian L. | Director | Grant | 25K | $0.00 | $0 | 100K |
| 2024-05-25 | LAPOINTE ANTHONY GREGG | Director | Grant | 25K | $0.00 | $0 | 100K |
| 2024-05-25 | MOOS WALTER H | Director | Grant | 25K | $0.00 | $0 | 102K |
| 2024-05-25 | Wasman Jane | Director | Grant | 25K | $0.00 | $0 | 100K |
| 2024-02-05 | RODRIGUEZ RAUL R | CEO, President | Sell | 31K | $1.14 | $35K | 2.0M |
| 2024-02-05 | Schorno Dean L | EVP & Chief Financial Officer | Sell | 7K | $1.14 | $8K | 403K |
| 2024-02-05 | Santos David A | EVP, Chief Commercial Officer | Sell | 9K | $1.14 | $10K | 349K |
| 2024-02-02 | RODRIGUEZ RAUL R | CEO, President | Sell | 22K | $1.13 | $25K | 2.1M |
| 2024-02-02 | Schorno Dean L | EVP & Chief Financial Officer | Sell | 6K | $1.13 | $6K | 410K |
| 2024-02-02 | Santos David A | EVP, Chief Commercial Officer | Sell | 6K | $1.13 | $6K | 358K |
| 2024-01-23 | Schorno Dean L | EVP & Chief Financial Officer | Grant | 209K | $0.00 | $0 | 416K |
| 2024-01-23 | Santos David A | EVP, Chief Commercial Officer | Grant | 209K | $0.00 | $0 | 364K |
| 2024-01-23 | RODRIGUEZ RAUL R | CEO, President | Grant | 400K | $0.00 | $0 | 2.1M |
| 2024-01-23 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | Grant | 209K | $0.00 | $0 | 214K |
| 2023-05-26 | HANNAH ALISON L. | Director | Grant | 25K | $0.00 | $0 | 56K |
| 2023-05-26 | Kotzin Brian L. | Director | Grant | 25K | $0.00 | $0 | 75K |
| 2023-05-26 | Ali-Jackson Kamil | Director | Grant | 25K | $0.00 | $0 | 44K |
| 2023-05-26 | MOOS WALTER H | Director | Grant | 25K | $0.00 | $0 | 77K |
| 2023-05-26 | LAPOINTE ANTHONY GREGG | Director | Grant | 25K | $0.00 | $0 | 75K |
| 2023-05-26 | LYONS GARY A | Director | Grant | 25K | $0.00 | $0 | 75K |
| 2023-05-26 | Wasman Jane | Director | Grant | 25K | $0.00 | $0 | 75K |
| 2023-02-06 | RODRIGUEZ RAUL R | CEO, President | Sell | 20K | $1.75 | $36K | 1.7M |
| 2023-02-02 | Dummer Wolfgang | EVP & CMO | Sell | 5K | $1.66 | $9K | 72K |
| 2023-02-02 | Schorno Dean L | EVP & Chief Financial Officer | Sell | 5K | $1.66 | $9K | 197K |
| 2023-02-02 | Santos David A | EVP, Chief Commercial Officer | Sell | 5K | $1.66 | $9K | 145K |
| 2023-01-26 | Santos David A | EVP, Chief Commercial Officer | Grant | 80K | $0.00 | $0 | 150K |
| 2023-01-26 | Schorno Dean L | EVP & Chief Financial Officer | Grant | 63K | $0.00 | $0 | 202K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON3 Form 144 notices on file for RIGL worth $306K at the prices reported; 0 in the last 90 days worth $0. Latest: Ali-Jackson Kamil filed on 2026-06-22 to sell 2,500 shares ($88K) from 2026-06-22.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-22 | Ali-Jackson KamilDirector | 3K | $88K | 0.014% | 2026-06-22 | Fidelity Brokerage Services LLC |
| 2026-05-26 | Ali-Jackson KamilDirector | 3K | $73K | 0.014% | 2026-05-26 | Fidelity Brokerage Services LLC |
| 2026-02-20 | MOOS WALTER HDirector | 4K | $145K | 0.022% | 2026-02-20 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON9 holders report 5% or more of RIGL in their latest filing, all on Schedule 13G (passive). The largest reported stake is Soleus Capital Master Fund, L.P. at 9.9% of the class (1,843,504 shares), filed 2026-08-13 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 1 | Armistice Capital, LLCinvestment adviser, other entity | 1.7M | 8.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Steven Boydparent holding company, individual | 1.7M | 8.9% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Soleus Capital Master Fund, L.P.non-US institution | 1.8M | 9.9% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Soleus Capital, LLCother entity | 1.8M | 9.9% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Soleus Capital Group, LLCother entity | 1.8M | 9.9% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Soleus Capital Management, L.P.partnership | 1.8M | 9.9% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Soleus GP, LLCother entity | 1.8M | 9.9% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Guy Levyindividual | 1.8M | 9.9% | 2026-06-30 |
| 2026-03-27 | 13G/Ano. 5 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-09 | 13G | STATE STREET CORPORATIONparent holding company | 1.1M | 6.0% | 2025-12-31 |
| 2025-10-07 | 13G/Ano. 1 | Morgan Stanleyparent holding company, corporation | 116K | 0.7% | 2025-09-30 |
| 2025-10-07 | 13G/Ano. 1 | Morgan Stanley Capital Services LLCbroker-dealer, corporation | 72K | 0.4% | 2025-09-30 |
13F holders
Tracked managers holding RIGL at their latest 13F. JSON5 of the 30 tracked managers held RIGL at their latest 13F, $43.6M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $21.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 543K | $21.2M | 0.01% | +97K |
| Two Sigma Investments | 2026-06-30 | 208K | $8.1M | 0.01% | -198K |
| Renaissance Technologies | 2026-06-30 | 146K | $5.7M | 0.01% | -193K |
| AQR Capital Management | 2026-06-30 | 125K | $4.9M | 0.00% | +34K |
| Millennium Management | 2026-06-30 | 94K | $3.7M | 0.00% | -171K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Rigel Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Rigel Pharmaceuticals (RIGL), SEC CIK 1034842, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-21.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-22.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-02.JSON and CSV
- Company record
- EDGAR filing index for CIK 1034842Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of RIGL is sold short?
2,732,739 shares were held short at the 2026-10-15 settlement, 12.8 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is RIGL's daily short volume?
On 2026-11-02, 34,241 of the 60,006 RIGL shares reported to FINRA were sold short, 57.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does RIGL have fails to deliver?
The SEC's latest file shows 287 RIGL shares failed to deliver at settlement 2026-09-21. Fails are reported per settlement date and published twice a month with a lag.
Are RIGL insiders buying or selling?
No open-market insider trades were reported for RIGL in the last 90 days. The most recent filings are listed below. Latest filing: Schorno Dean L (EVP & Chief Financial Officer) on 2026-09-02.
Have RIGL insiders filed to sell?
3 Form 144 notices on file for RIGL worth $306K at the prices reported; 0 in the last 90 days worth $0. Latest: Ali-Jackson Kamil filed on 2026-06-22 to sell 2,500 shares ($88K) from 2026-06-22.
Who owns 5% or more of RIGL?
9 holders report 5% or more of RIGL in their latest filing, all on Schedule 13G (passive). The largest reported stake is Soleus Capital Master Fund, L.P. at 9.9% of the class (1,843,504 shares), filed 2026-08-13 for an event on 2026-06-30.
Which tracked 13F managers own RIGL?
5 of the 30 tracked 13F managers held RIGL shares at their latest filing, $43.6M in all. The largest: D. E. Shaw & Co. (543K shares, $21.2M), Two Sigma Investments (208K shares, $8.1M), Renaissance Technologies (146K shares, $5.7M), Cliff Asness's AQR Capital Management (125K shares, $4.9M), Izzy Englander's Millennium Management (94K shares, $3.7M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.